by Francisca Peixoto | Oct 8, 2024 | Uncategorized
We are excited to announce another exciting addition to LifeLink’s portfolio. Arda Therapeutics $43M Series A was led by Andreessen Horowitz (a16z) Bio with participation from Eli Lilly and Company Ventures, GV (Google Ventures), Two Sigma Ventures, RV Invest,...
by Francisca Peixoto | Oct 1, 2024 | Uncategorized
Our portfolio company Spiral Therapeutics just announced successful completion of the SPT-2101 phase 1b/2a clinical trial for Meniere’s disease, with promising results. Spiral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing...
by Francisca Peixoto | Aug 9, 2024 | Uncategorized
Ana is a biotechnologist with more than 8 years of R&D experience across various biomedical research fields. She earned her Master’s degree in Biomedical Sciences from Utrecht University (the Netherlands) and a Ph.D. in Regenerative Therapies from Charité...
by Francisca Peixoto | Jul 31, 2024 | Uncategorized
We are excited to announce our participation in AIRNA’s oversubscribed $60 million financing. AiRNA is an incredible biotech company focused on developing RNA editing therapeutics. This investment was led by our colleagues at Forbion and ARCH Venture Partners...
by Francisca Peixoto | Jun 13, 2024 | Uncategorized
Our portfolio company Ochre Bio just announced a new, multi-year, data licence agreement with GSK. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. This partnership will provide GSK with...
